Compare Eni SpA (E) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Tango Therapeutics Inc. — how do they compare? Eni SpA trades at $58.97 (market cap $82.04B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Eni SpA is far larger — about 21.9× Tango Therapeutics Inc.'s market cap, and Eni SpA pays a 4.25% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Tango Therapeutics Inc. for 0 Days on average.
| E | TNGX | |
|---|---|---|
Market Cap | $82.04B | $3.75B |
Volume | 245,093 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $57.71 | $32.90 |
52-Week Low | $34.20 | $7.50 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $106.48B | $2.77B |
Dividend Yield | 4.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $57.71, up 1.66% today, with strong technical momentum and bullish moving average signals. The stock shows attractive valuation metrics with P/E of 13.35 and P/S of 0.88, though recent earnings missed expectations in Q1 and Q2 2026. Revenue has declined from $132.5B in 2022 to $82.2B in 2025, but net income margin improved to 5.97% in 2026 projections. Recent developments include expansion in Venezuela oil opportunities and humanoid robotics partnerships.
The outlook remains cautiously optimistic with 34.6% analyst buy ratings and improving profitability margins. Key opportunities include Venezuela oil expansion and cost discipline, while risks involve revenue volatility and execution challenges. The stock presents value characteristics with reasonable valuation, though investors should monitor earnings consistency and global energy market conditions.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
